首页|血红蛋白类氧载体在肿瘤治疗领域中的应用进展

血红蛋白类氧载体在肿瘤治疗领域中的应用进展

扫码查看
大多数实体肿瘤内血流和氧气供氧不足,缺氧微环境会加速肿瘤恶化,影响肿瘤预后。因此,改善肿瘤组织的氧合状态对提高肿瘤治疗敏感性和有效性至关重要。血红蛋白类氧载体(hemoglobin-based oxygen carriers,HBOCs)是一类携释氧纳米粒子,可到达正常红细胞难以通过的障碍性微循环小血管,为缺氧的组织器官输送氧气。已有研究证明,HBOCs作为 1 种潜在的纳米级高效携/释氧剂应用于肿瘤治疗可以增加组织氧合,在肿瘤治疗领域具有巨大应用前景。本文综述了缺氧在肿瘤中的影响,并重点介绍了血红蛋白类氧载体在肿瘤放疗、化疗、新型动力学治疗和免疫治疗领域的应用进展及可能机制。
Application progress of hemoglobin-based oxygen carriers(HBOCs)in tumor therapy
Most solid tumors suffer from inadequate blood perfusion and oxygenation,leading to a hypoxic microenviron-ment that accelerates tumor progression and adversely impacts prognosis.Thus,improving oxygenation in tumor tissues is crucial for enhancing the sensitivity and efficacy of tumor therapy.Hemoglobin-based oxygen carriers(HBOCs),as a type of oxygen-carrying nanoparticles,can not only carry and release oxygen but also reach the small blood vessels of obstructive mi-crocirculation to deliver oxygen for anoxic tissues and organs,which are difficult for normal red blood cells to pass through.Studies have demonstrated that the application of HBOCs as a potential nanoscale efficient oxygen carrier in tumor therapy can enhance tissue oxygenation and hold great promise for applications in tumor therapy.This review summarizes the impact of hypoxia in tumors and highlights the progress and potential mechanisms of using HBOCs in tumor radiotherapy,chemo-therapy,new kinetic therapy and immunotherapy.

hemoglobin-based oxygen carriers(HBOCs)tumor microenvironmenttumor hypoxiatumor therapy

郑诗凡、王红、徐莹璨、吴嘉康、周文涛、郝莎莎

展开 >

中国医学科学院北京协和医院输血研究所,四川 成都 610052

血红蛋白类氧载体 肿瘤微环境 肿瘤缺氧 肿瘤治疗

中国医科院医学与健康科技创新工程项目

2021-I2M-1-060

2024

中国输血杂志
中国输血协会 中国医学科学院输血研究所

中国输血杂志

CSTPCD
影响因子:1.279
ISSN:1004-549X
年,卷(期):2024.37(4)
  • 47